 |
Jaehyung Yoon
|
08/26/09 11:05 PM |
ONTY
|
Analysis |
Assigning a value to development-stage
biotech companies is a questionable task, and generally requires
more intangible assumptions (market potential, clinic...
|
1832
|
1
|
|
Jaehyung Yoon
|
08/10/09 2:00 PM |
GENZ
|
News |
I don't know enough to compare/contrast
Genzyme and Shire in depth, but here are the major differences on
the surface: Genzyme is a biotechnology company, a...
|
50
|
1
|
|
Jaehyung Yoon
|
08/07/09 8:45 AM |
GENZ
|
News |
Genzyme's blockbuster product in the
genetic disorder is Cerezyme for Gaucher diseases. Comparable
to the blockbuster are Shire's velaglucerase alfa an...
|
54
|
2
|
|
